Researchers have developed a soft contact lens embedded with electrical stimulation electrodes that, in a mouse model of ...

Researchers have demonstrated a promising new approach to stopping pancreatic cancer before it starts, using experimental drugs to eliminate microscopic precancerous lesions in the pancreas.

For most children diagnosed with medulloblastoma, the most common malignant pediatric brain tumor, survival rates are encouraging. But for a subset, remission is not the end of the story. Roughly 30% ...

NIR-II imaging has many advantages for preclinincal research as it supports deeper visualization with lower scattering and autofluorescence.

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...

CollPlant's 3D bio-printed regenerative breast implant bioprinted with rhCollagen on a Stratasys 3D printed. The implant is undergoing a pre-clinical study to explore regenerative breast tissue growth ...

A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Manuka honey could potentially be an alternative, natural option for breast cancer prevention and ...

PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) , a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, ...

Cedars-Sinai investigators have identified a "molecular switch" on a gene strongly associated with the autoimmune disease lupus, which appears to propel immune cells into overdrive, attacking and ...

REHOVOT, Israel & EDEN PRAIRIE, Minn., Aug. 19, 2024 /PRNewswire/ -- In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd.

An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study. The preclinical study combined the analysis ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of inhibitor ...